# Eureka Therapeutics, Inc.

> Eureka Therapeutics is a clinical-stage biopharmaceutical company in Emeryville, California, developing next-generation T-cell therapies for cancer, with a focus on hard-to-treat solid tumors. Founded in 2006 by Dr. Cheng Liu, the company pairs its E-ALPHA phage-display antibody engine with its ARTEMIS T-cell receptor platform - an alternative to conventional CAR-T designed to keep engineered T cells potent inside immunosuppressive tumors while sharply reducing the inflammatory cytokine release linked to CAR-T toxicity. Its lead program, ECT204, targets GPC3-positive advanced liver cancer and has received FDA RMAT designation.

- **Founded:** 2006
- **Headquarters:** Emeryville, California, United States
- **Founders:** Cheng Liu (Founder, President & CEO, Chairman)
- **Team size:** ~51 employees
- **Products:** ARTEMIS T-Cell Receptor Platform, E-ALPHA Antibody Discovery Platform, ECT204 (AbTCR / ARTEMIS), ET190L1 (ARTEMIS)
- **Notable:** FDA RMAT (Regenerative Medicine Advanced Therapy) designation for ECT204 in advanced hepatocellular carcinoma, ARYA-3 clinical trial advanced to Phase II in 2024 for GPC3-positive liver cancer, FDA IND allowance for ET190L1 ARTEMIS therapy in CD19+ non-Hodgkin lymphoma

## Products & services

- **ARTEMIS T-Cell Receptor Platform** — A proprietary alternative to the conventional chimeric antigen receptor (CAR). The ARTEMIS receptor regulates T-cell activation and cytokine release upon engaging tumor cells, aiming to match CAR-T potency while reducing inflammatory cytokine release, improving tumor infiltration, safety and T-cell persistence.
- **E-ALPHA Antibody Discovery Platform** — A phage-display platform using high-throughput screening to discover cancer-specific and TCR-mimic antibodies, including antibodies that recognize intracellular targets (such as AFP) presented as peptide-MHC complexes.
- **ECT204 (AbTCR / ARTEMIS)** — Lead autologous ARTEMIS CAR (AbTCR) T-cell therapy targeting GPC3-positive advanced hepatocellular carcinoma, evaluated in the Phase I/II ARYA-3 trial. Granted FDA RMAT designation.
- **ET190L1 (ARTEMIS)** — ARTEMIS T-cell therapy targeting CD19 for relapsed and refractory CD19-positive non-Hodgkin lymphoma; received FDA IND allowance.

## Achievements

- FDA RMAT (Regenerative Medicine Advanced Therapy) designation for ECT204 in advanced hepatocellular carcinoma
- ARYA-3 clinical trial advanced to Phase II in 2024 for GPC3-positive liver cancer
- FDA IND allowance for ET190L1 ARTEMIS therapy in CD19+ non-Hodgkin lymphoma
- NCI-led study of ARTEMIS CAR T cells published in Cell Reports Medicine
- Founder Dr. Cheng Liu holds 500+ patents (100+ issued worldwide) and received Special U.S. Congressional Recognition in 2007
- Raised over $170 million to advance solid-tumor cell therapy

## Latest updates

- **2024-03** — Eureka advanced its ARYA-3 clinical trial to Phase II for GPC3-targeting ARTEMIS T-cell therapy (ECT204) in liver cancer.
- **2023-05** — Completed $20M debt financing to support pipeline advancement.
- **2023** — NCI-led study in Cell Reports Medicine showed ARTEMIS CAR T cells retaining activity in immunosuppressive, low-antigen solid-tumor environments.
- **2022** — Announced strategic collaboration with Imugene combining oncolytic virus and ARTEMIS T-cell therapy for solid tumors.

## Links

- Website: https://eurekatherapeutics.com
- LinkedIn: http://www.linkedin.com/company/eureka-therapeutics-inc
- Twitter/X: https://twitter.com/EurekaThera
- YouTube: https://www.youtube.com/@eurekatherapeutics
- Facebook: https://www.facebook.com/eurekatherapeutics

---

Profile page: https://yespress.io/eureka-therapeutics-inc
Published by YesPress — https://yespress.io
Last updated: 2026-07-15